Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market by Product Type (Synthesized Oligonucleotide, Reagents & Consumables, and Equipment), Application (Research, Therapeutic, and Diagnostic), End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Diagnostic Laboratories and CROs & CMOs), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of genetic disorders and cancer, increasing use of oligonucleotide in therapeutics, advancements in genomics research, and growing product development activities across the globe.

The oligonucleotide synthesis market was valued at USD 3,443.49 million in 2024, growing at a CAGR of 10.02% during the forecast period from 2025 to 2032 to reach USD 7,357.08 million by 2032. The rising prevalence of genetic disorders is a key driver of the growing demand for oligonucleotide synthesis, as these molecules play a vital role in gene therapies and diagnostics targeting hereditary diseases. The expanding use of oligonucleotides in therapeutics particularly antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) has opened new avenues for treating conditions such as spinal muscular atrophy and hereditary amyloidosis.  

Advancements in genomics research, including next-generation sequencing (NGS) and CRISPR-based gene editing, further propel market growth by relying on custom-designed oligonucleotides for precise and efficient applications. These technologies have significantly enhanced the accuracy of genetic analyses, enabling early diagnosis and personalized treatment strategies for various genetic conditions.  

Moreover, intensified product development activities, strategic collaborations, and partnerships among key market players are fostering innovation and improving production efficiency. These efforts have expanded the range of applications for oligonucleotide synthesis beyond healthcare, encompassing areas like agriculture, biotechnology, and forensic science.  Collectively, these factors are expected to drive the global oligonucleotide synthesis market’s growth during the forecast period from 2025 to 2032.  

Oligonucleotide Synthesis Market Dynamics:

According to the National Organization for Rare Disorders (2024), Duchenne muscular dystrophy (DMD) is a rare but one of the most common genetic muscle disorders, affecting approximately 1 in 3,500 male births worldwide. Typically diagnosed between the ages of three and six, DMD leads to progressive muscle degeneration and currently has no definitive cure, creating a significant demand for advanced treatment options. Oligonucleotide-based therapies, particularly exon-skipping drugs, have emerged as transformative solutions for DMD, thereby propelling the oligonucleotide synthesis market. For instance, in February 2021, the FDA approved Amondys 45 (casimersen) for treating DMD. This drug utilizes synthetic antisense oligonucleotides (ASOs) to skip specific exons during RNA splicing, enabling partial production of functional dystrophin protein.

Additionally, the International Agency for Research on Cancer (2024) reported that in 2022, there were an estimated 20 million new cancer cases globally, with projections indicating a rise to 32.6 million by 2045. Oligonucleotides, including ASOs and small interfering RNA (siRNA), play a vital role in cancer research and treatment by silencing genes associated with tumor growth and chemotherapy resistance. With the increasing incidence of cancer, particularly among aging populations, the demand for targeted therapies is surging. Oligonucleotide-based treatments are proving promising for addressing genetic mutations in various cancers, including lung, breast, and colorectal cancers, further driving the global oligonucleotide synthesis market.

Breakthroughs in genomics have deepened our understanding of gene expression, mutations, and regulation, spurring the development of oligonucleotide-based therapies for previously untreatable genetic and chronic conditions, such as neurodegenerative diseases and rare genetic disorders. Moreover, advancements in next-generation sequencing (NGS) and CRISPR technologies have amplified the need for high-quality synthetic oligonucleotides, which serve as essential reagents in genetic editing, diagnostics, and research. These technologies are broadening the scope of oligonucleotide applications in both clinical and therapeutic settings, further fueling market growth.

Despite these advancements, the production of therapeutic-grade oligonucleotides presents challenges. The process involves complex and costly steps, including rigorous purification and quality control measures. Additionally, stringent regulatory requirements for clinical trials and product approvals may pose obstacles to market expansion.

Nevertheless, the aforementioned factors are expected to significantly boost the global oligonucleotide synthesis market during the forecast period from 2025 to 2032.

Oligonucleotide Synthesis Market Segment Analysis:

Oligonucleotide Synthesis Market by Product Type (Synthesized Oligonucleotide, Reagents & Consumables, and Equipment), Application (Research, Therapeutic, and Diagnostic), End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Diagnostic Laboratories and CROs & CMOs), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)   

In the product type segment of the oligonucleotide synthesis market, the synthesized oligonucleotides category is expected to hold a significant share in 2024. Synthesized oligonucleotides are a cornerstone of the market, driving overall growth due to their broad applications across research, diagnostics, and therapeutics. These short, single-stranded DNA or RNA sequences are essential tools in molecular biology, enabling precise genetic manipulation, targeted diagnostics, and innovative therapies.

In research, synthesized oligonucleotides are widely utilized in polymerase chain reaction (PCR) and sequencing technologies, which form the foundation for genomic studies, drug discovery, and gene editing. In diagnostics, they play a crucial role in developing assays to detect infectious diseases, genetic mutations, and cancer biomarkers—demand for which is increasing amid the rise of personalized medicine.

Therapeutically, synthesized oligonucleotides have revolutionized drug development. Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), designed to target specific genetic sequences, are being used to treat rare genetic disorders, cancer, and cardiovascular diseases. Notable FDA-approved oligonucleotide-based drugs include Spinraza (for spinal muscular atrophy) and Givlaari (for acute hepatic porphyria), underscoring their clinical potential. For instance, in January 2024, Vanda Pharmaceuticals Inc. announced that the U.S. FDA approved the Investigational New Drug (IND) application for VCA-894A, aimed at treating Charcot-Marie-Tooth disease, axonal type 2S (CMT2S), caused by cryptic splice site variants in the IGHMBP2 gene. VCA-894A is a novel ASO designed to target a cryptic splice site variant within this gene, highlighting the expanding scope of oligonucleotide-based therapies.

Advancements in chemical synthesis technologies, particularly automated synthesis platforms, have significantly improved the scalability, efficiency, and precision of oligonucleotide production. This has enabled the development of more complex therapeutic oligonucleotides, such as aptamers and CRISPR guide RNAs, further broadening market applications. Additionally, major players like Thermo Fisher Scientific, Integrated DNA Technologies (IDT), and Agilent Technologies are making substantial investments in producing high-quality, modified oligonucleotides for both research and therapeutic purposes, thereby reinforcing market expansion.

Given these factors, the synthesized oligonucleotides segment is poised to experience significant growth, thereby driving the overall global oligonucleotide synthesis market during the forecast period.

North America is expected to dominate the overall oligonucleotide synthesis market:

North America is expected to account for the largest share of the oligonucleotide synthesis market in 2024. This dominance is driven by the region's advanced healthcare infrastructure, substantial investments in genomic research, and the strong presence of key market players. North America leads in drug development, particularly in antisense and small interfering RNA (siRNA)-based therapies, which are increasingly adopted for treating cancer, genetic disorders, and infectious diseases. Supportive regulatory frameworks, such as expedited FDA approvals for innovative oligonucleotide therapies, further bolster market growth. Additionally, government funding and private sector initiatives focused on precision medicine and personalized therapeutics strengthen the market landscape. The high prevalence of chronic diseases and a well-established biotechnology sector further solidify North America's leadership in oligonucleotide synthesis.

According to recent data from Johns Hopkins, more than 15,000 Americans currently live with Huntington's disease. The same source notes that if a parent has Huntington's disease, their child has a 50% chance of developing the condition; if the child does not develop the disease, it is not passed to subsequent generations. Oligonucleotide-based therapies, such as antisense oligonucleotides (ASOs), are specifically designed to target and reduce the production of the toxic mutant huntingtin protein responsible for disease progression. The rising demand for precision medicine for Huntington's disease, combined with advancements in delivery mechanisms and clinical trials for ASO therapies, has increased the need for high-quality oligonucleotide synthesis.

Furthermore, data from the International Agency for Research on Cancer (2024) reveals that in 2022, North America recorded an estimated 2.67 million new cancer cases, with projections indicating an increase to 3.83 million by 2045. Cancer, characterized by genetic mutations and dysregulated gene expression, is a prime target for oligonucleotide-based interventions. Therapies such as ASOs and siRNAs work by silencing oncogenes or reactivating tumor suppressor genes, thereby addressing the genetic roots of cancer. For cancers with complex genetic profiles such as breast, lung, and colorectal cancers oligonucleotide-based treatments offer a promising approach to modulate specific molecular pathways involved in tumor growth and resistance to therapy. This, in turn, drives the demand for oligonucleotide synthesis across the region.

Considering these factors, North America’s oligonucleotide synthesis market is poised for significant growth during the forecast period.

Oligonucleotide Synthesis Market Key Players:

Some of the key market players operating in the oligonucleotide synthesis market include Thermo Fisher Scientific Inc., Agilent Technologies, Merck KGaA, Bio-Synthesis Inc., Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, TriLink Biotechnologies, Sarepta Therapeutics, and others.

Recent Developmental Activities in the Oligonucleotide Synthesis Market:

• In June 2024, GSK completed the acquisition of Elsie Biotechnologies for USD 50 million to strengthen its oligonucleotide research and development capabilities.
• In April 2024, Asahi Kasei Bioprocess agreed with Axolabs to build a 59,000-square-foot oligonucleotide cGMP manufacturing facility in Germany.

Key Takeaways From the Oligonucleotide Synthesis Market Report Study

• Market size analysis for current oligonucleotide synthesis size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the oligonucleotide synthesis market.
• Various opportunities available for the other competitors in the oligonucleotide synthesis market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current oligonucleotide synthesis market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for oligonucleotide synthesis market growth in the coming future?

Target Audience Who Can be Benefited from This Oligonucleotide Synthesis Market Report Study

• Oligonucleotide synthesis product providers
• Research organizations and consulting companies 
• Oligonucleotide synthesis-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in oligonucleotide synthesis 
• Various end-users who want to know more about the oligonucleotide synthesis market and the latest technological developments in the oligonucleotide synthesis market.  

Frequently Asked Questions for the Oligonucleotide Synthesis Market:

1. What is oligonucleotide synthesis?

• Oligonucleotide synthesis is the chemical process of creating short DNA or RNA strands with a specific sequence. These synthetic molecules are widely used in research, diagnostics, and therapeutics, such as gene editing, PCR, and targeted drug delivery.

2. What is the market for oligonucleotide synthesis?

• The oligonucleotide synthesis market was valued at USD 3,443.49 million in 2024, growing at a CAGR of 10.02% during the forecast period from 2025 to 2032 to reach USD 7,357.08 million by 2032. 

3. What are the drivers for the global oligonucleotide synthesis market?

• The increasing prevalence of genetic disorders is driving demand for oligonucleotide synthesis, as these molecules play a crucial role in gene therapies and diagnostics targeting hereditary diseases. The growing use of oligonucleotides in therapeutics, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), has opened new avenues for treating conditions like spinal muscular atrophy and hereditary amyloidosis. Additionally, advancements in genomics research, including next-generation sequencing (NGS) and CRISPR-based gene editing, rely heavily on custom-designed oligonucleotides, further accelerating market growth. Furthermore, intensified product development activities by key players and collaborations worldwide are fostering innovation, improving efficiency, and expanding the applications of oligonucleotide synthesis in healthcare and beyond. These factors collectively contribute to the increasing need for oligonucleotide synthesis, boosting the overall market of oligonucleotide synthesis during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global oligonucleotide synthesis market?

• Some of the key market players operating in the oligonucleotide synthesis are Thermo Fisher Scientific Inc., Agilent Technologies, Merck KGaA, Bio-Synthesis Inc., Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, Nitto Avecia, Ribo Biotechnology, STA Pharmaceutical, Sumitomo Chemical, TriLink Biotechnologies, Sarepta Therapeutics, and others.

5. Which region has the highest share in the global oligonucleotide synthesis market?

• North America is expected to dominate the oligonucleotide synthesis market in 2024 due to its advanced healthcare infrastructure, significant investments in genomic research, and the presence of key market players. The region leads in drug development, including antisense and siRNA-based therapies, with increasing adoption for treating cancer, genetic disorders, and infectious diseases. Supportive regulatory frameworks, like FDA approvals for innovative oligonucleotide therapies, further drive market growth. Additionally, government funding and private sector initiatives for precision medicine and personalized therapeutics strengthen the market. The growing prevalence of chronic diseases and a well-established biotechnology sector position North America as a leader in oligonucleotide synthesis.